A new report from Research and Markets and GlobalData, "Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018," indicates that the global tuberculosis (TB) infection market was worth $38.3 million in 2010. It is expected to decline at a compound annual growth rate (CAGR) of 4.5 percentÂ during the next eight years to reach $26.6 million by 2018.
According to the report, the TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. Cure rates have been improved with the conventional Directly Observed Therapy (DOTS). Multidrug-resistant tuberculosis (MDR-TB) was a consequence of patient non-compliance and the long duration of therapy. Companies are actively developing products for the prophylaxis and cure of TB with shorter treatment durations. Two not-for-profit organizations - TB Alliance and the Aeras Global TB Vaccine Foundation - have partnered with pharmaceutical players to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is likely to decline as no launches are expected until 2018.